Article Details
Retrieved on: 2017-12-20 23:17:25
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Just last week, for example, startup Pionyr Immunotherapeutics Inc. of San Francisco said it raised $92 million from New Enterprise Associates, <b>Sofinnova</b> <b>Ventures</b> Vida Ventures and others to move forward with two antibody treatments, including one it hopes to be in the clinic in mid- to late 2019.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here